about
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritisA method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseasesReceptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markersIdentification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeansA genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritisAnti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage.Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammationHigh-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci.EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden.Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritisSurvivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study.Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity.Novel risk genes for systemic lupus erythematosus predicted by random forest classificationTransancestral mapping and genetic load in systemic lupus erythematosus.Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis.Erratum to: Concentration of antibodies against Porphyromonas gingivalisis increased before the onset of symptoms of rheumatoid arthritis.No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis: results from a nested case-control study.Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease.Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden.Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis.Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinMetabolic responses to change in disease activity during tumor necrosis factor inhibition in patients with rheumatoid arthritis.Glucocorticoid treatment increases density of serotonin 5-HT2A receptors in humans.Correction: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.Unexpected finding of a marked non-neuronal cholinergic system in human knee joint synovial tissue.CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis.The Extent of Subclinical Atherosclerosis Is Partially Predicted by the Inflammatory Load: A Prospective Study over 5 Years in Patients with Rheumatoid Arthritis and Matched Controls.Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.Delays in assessment of patients with rheumatoid arthritis: variations across Europe.Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis.High sodium chloride consumption enhances the effects of smoking but does not interact with SGK1 polymorphisms in the development of ACPA-positive status in patients with RA.
P50
Q24805387-8B5C7D1F-A655-4CAF-A4A3-EE60F3DF0372Q30276804-A9CA64D5-64C7-4BDD-85FF-E2FB368CFB7EQ33592037-EC8CE9B1-2DAC-4E4A-9D9F-2C2AB7EC1C7EQ33765844-5BC1E7F0-77BF-45AA-A4F1-37CA3F137260Q34125266-8976FCDA-0127-46C4-B668-9141C268E108Q34805476-EDD847FA-EFC4-4973-B3F5-61E8EA34820AQ35053861-21504532-5A6D-48E9-A28A-3A19981CAA92Q35149378-0A56E473-A6B5-461E-A5E8-8BC5255637FFQ35636880-A7198EAA-0414-4DDD-BE48-78B1003516A8Q35744106-864DECA2-80B0-4403-91E8-113BDDBA0FE8Q35896648-B0937FDA-F89F-47D7-B568-21E8EA3EF8ABQ36020173-3F9EBDD6-37FE-436B-AE03-C2DA5B6A3BA2Q36965739-CB2FACBF-0159-4EB8-A140-2E4233B21EB8Q37689919-54C1B552-BA66-49F9-A3DC-58FB9C783642Q37693227-5D9DC742-0280-4839-AA2D-69E7B87FD763Q38663531-F3829EFA-3A0D-4B47-83DC-FF3BBF9BC062Q38676110-EC17817A-3209-47DE-AA34-6B8413180A3BQ39137986-08BC046A-CF81-4338-9680-A277B59137F4Q42373545-7639BC95-F19A-4AEB-BD22-63D72B7D3E8AQ42635206-E570D1DE-47A1-4E23-AB74-5528E6E55C43Q42681406-6E4F642F-6366-4A37-A9FF-A1AC11936511Q43635182-FA6C2378-E1B4-4902-A83B-64CE20C33A23Q43956903-F27D7AC8-58C7-41CB-9484-DC988016CE10Q44001426-7EE627CF-6701-422D-B576-99B9CD4E6E48Q44083110-384F9AA4-EA8F-4DCA-B3A8-50C11D965EADQ44293608-8385F2C9-339F-489A-9512-8ACE67A22F5AQ44455056-B7A3D235-AC5A-44DA-AC41-67D84060C8F8Q44536841-F789A9F6-E7DF-4A73-BA46-6AAFA38188EBQ44616885-1193FDD3-9B85-4CD0-AFAC-7E1B038B1777Q45178819-F9FA00F8-4171-40BB-979E-9EA2B130EA27Q45733308-852D7DD7-2712-4207-ACB4-52EAE319EE5DQ45736719-D33AA0BC-E797-40D4-921F-1A6F7F642952Q45907738-8EA0216D-903E-4C74-8F2B-DABF83383A95Q46487713-96FAD773-06A5-4FBE-924E-2ABD09AB95E2Q47797398-F6B7087F-0F20-4FDF-8D39-0048E3D27301Q50851596-CD3CF4C3-ADED-4C08-A9B7-ADD77A884C00Q51681527-52CE6FF0-4480-4FAF-9EC2-842A123CBD6AQ52893591-4D752E15-C989-4371-84E6-1CDB383AB956Q53392803-9701BD68-4DB6-4695-86EF-11D195769952Q55030490-919530E3-8B65-4C34-866C-D0C198A9E406
P50
description
Professor, senior vid Institutionen för folkhälsa och klinisk medicin Enhet: Reumatologi
@sv
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Solbritt Rantapää Dahlqvist
@ast
Solbritt Rantapää Dahlqvist
@en
Solbritt Rantapää Dahlqvist
@es
Solbritt Rantapää Dahlqvist
@nl
Solbritt Rantapää Dahlqvist
@sl
Solbritt Rantapää Dahlqvist
@sv
type
label
Solbritt Rantapää Dahlqvist
@ast
Solbritt Rantapää Dahlqvist
@en
Solbritt Rantapää Dahlqvist
@es
Solbritt Rantapää Dahlqvist
@nl
Solbritt Rantapää Dahlqvist
@sl
Solbritt Rantapää Dahlqvist
@sv
prefLabel
Solbritt Rantapää Dahlqvist
@ast
Solbritt Rantapää Dahlqvist
@en
Solbritt Rantapää Dahlqvist
@es
Solbritt Rantapää Dahlqvist
@nl
Solbritt Rantapää Dahlqvist
@sl
Solbritt Rantapää Dahlqvist
@sv
P1006
P1015
P214
P227
P5587
P906
P1006
P1015
P106
P108
P21
P213
0000 0003 8194 8268
P214
P227
1146728565
P31
P496
0000-0001-8259-3863
P5587
jgvxzcg22gchckx
P569
1947-08-23T00:00:00Z
P7859
viaf-263602192